ECTRIMS2015

FDA Grants ‘Breakthrough Therapy’ Designation to Genentechā€™s Ocrelizumab for PPMS

Genentech recently announced that the U.S. Food and Drug Administration (FDA) granted its investigational medicine ocrelizumab, a potential treatment forĀ primary progressive multiple sclerosis (PPMS),Ā Breakthrough Therapy DesignationĀ based on positiveĀ Phase 3 clinical trial results showing thatĀ ocrelizumab significantly reduced disability progression and other disease activity markers compared toĀ placebo. The FDA designation is…

Mike Nace, Editor-in-Chief of Multiple Sclerosis News Today, Reviews Day 2-3 at #ECTRIMS2015

https://multiplesclerosisnewstoday.com/wp-content/uploads/2015/10/ECTRIMS-Podcast-2-091015-8.32-pm.mp3   Read theĀ articles mentioned in theĀ podcast: #ECTRIMS2015 ā€“ Another Attendee Record #ECTRIMS2015 ā€“ ā€œVitamin D plays important role in MS inflammation.ā€ ā€“ Jorge Correale #ECTRIMS2015 ā€“ ā€œWhen you stop smoking you can decrease the risk of disease progression.ā€ ā€“ Jorge Correale Discovering a New World in…

MS Care: A Hot Topic at #ECTRIMS2015

Three ā€œHot Topic Sessionsā€ on multiple sclerosis will take place this afternoon (17:00 ā€“ 17:45 h, GMT + 1h) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently being held in Barcelona, Spain, October 7 ā€“ 10. The first session is entitled…

Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015

Biogen is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatmentĀ forĀ relapsing-remitting multiple sclerosis (RRMS), during theĀ 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) happening now in Barcelona, Spain until October 10, 2015. The…